Maxygen Announces $10 Million Stock Repurchase Program
[Business Wire] - Maxygen, Inc. , a biotechnology company, today announced that its Board of Directors has approved a new stock repurchase program under which the company may purchase up to $10.0 million of its common stock through December 31, 2012.

34 Stocks With Over 10% Return On Equity Selling For Less Than Book, Part 6: Services

Prolor Biotech: De-Risked And Ready To Begin Phase 3 Trials

3 Attractive, Low P/E Ratio Stocks And More With Safe Credit Scores

MAXYGEN INC Financials

MAXYGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Maxygen Announces BARDA Decision Not To Award Contract for Development of MAXY-G34 for Acute Radiation Syndrome
[Business Wire] - Maxygen, Inc. today announced that it has been advised by the Biomedical Advanced Research and Development Authority that Maxygen?s proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome will not be considered for a contract award.

MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits